ReviewClinical ophthalmology (Auckland, N.Z.)2020
Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy.
Review in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05587231 (Comparison of the Postoperative Use of Dextenza), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Postoperative Use of Dextenza (Dexamethasome Ophthalmic Insert) vs a Standard Regimen of Topical Fluorometholone After PRK
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Safety and Comfort of an Innovative Drug Delivery Device in Healthy Subjects.Translational vision science & technology · 2020Trial
- Enzyme-Instructed Self-Assembling Peptide Hydrogels for Sustained Subconjunctival Delivery of Dexamethasone: A Stereochemical Comparison of L- and D-Enantiomeric Peptides for Postoperative Ocular Anti-Inflammatory Therapy.Gels (Basel, Switzerland) · 2026Article
- Advances in the management of ocular anterior segment diseases using biomaterials-based drug delivery systems.Journal of biomaterials applications · 2026Review
- Thermoresponsive antioxidant metal-free carbon nanodot hydrogel: An effective therapeutic approach for ocular surface disease.Science advances · 2025Article
- The Efficacy and Safety of Dexamethasone Intracanalicular Insert Use in Patients with Chronic Seasonal/Perennial Allergic Conjunctivitis: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Controlled Drug Delivery Device for Cornea Treatment and Novel Method for Its Testing.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Dexamethasone-loaded keratin films for ocular surface reconstruction.Journal of materials science. Materials in medicine · 2022Article
- Associated risk factors of postoperative pain after glaucoma surgery: a prospective study.International ophthalmology · 2022Article
- In Clinic Optometrist Insertion of Dextenza (Dexamethasone Ophthalmic Insert 0.4mg) Prior to Cataract Surgery: The PREPARE Study.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Plasma Pharmacokinetic Parameters of Dexamethasone Following Administration of a Dexamethasone Intracanalicular Insert in Healthy Adults.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Article
- A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK).Clinical ophthalmology (Auckland, N.Z.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation and pain are two prevalent findings after ocular surgery. Corticosteroids are widely administrated as a core treatment to control post-surgical inflammation and pain. Improper patient adherence to post-operative eye drop regimens, limited bioavailability of topical eye drops, and the negative impact of preservatives used in many of these eye drops, has made a strong case for novel therapies in the treatment of post-operative pain and inflammation. This review of the literature will focus on the role of intracanalicular sustained-release dexamethasone (Dextenza, Ocular Therapeutix, Bedford, MA, USA) for the management of ocular inflammation and pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.